Uses
Midecamycin Acetate is a macrolide antibiotic, a derivative of edithromycin. It is tasteless, easily administered orally, and exerts its antibacterial effect by binding to the 70S ribosomes of bacteria and inhibiting protein synthesis. It is used to treat infections caused by susceptible Staphylococcus spp., hemolytic streptococci, pneumococci, Peptococcus spp., Haemophilus influenzae, Bordetella pertussis, and Mycoplasma spp., such as folliculitis, boils, cellulitis, whitlow, subcutaneous abscesses, infectious sebaceous cysts, pharyngitis, tonsillitis, bronchitis, pneumonia, primary atypical pneumonia, pertussis, otitis media, and periodontitis.
Pharmaceutical Applications
A semisynthetic diacetyl derivative of midecamycin A1. It is generally less active than erythromycin and some strains of H. influenzae and E. faecalis are resistant. It is rapidly and extensively metabolized, though some metabolites retain antibacterial activity.
Absorption of the dry formulation is unaffected by food, whereas that of the oral suspension is delayed. In various studies the peak plasma concentration was 1.65, 1.31–3 and 1.3–2.7 mg/L after doses of 400, 600 and 800 mg, respectively.
It is said to exhibit less toxicity than earlier macrolides. Attention has been paid to its interaction with theophylline, which resembles that of other macrolides. It is of limited availability.
